A phase 3 study of the efficacy, safety, and pharmacokinetics profile of subcutaneous vs intravenous nivolumab + relatlimab fixed-dose combination in previously untreated metastatic or unresectable melanoma (RELATIVITY-127)

Bibliographic Details
Main Authors:	G.V. Long, R. Gutzmer, A. Haydon, E. Muñoz Couselo, C. Lebbé, M. Carlino, W. Chow, F. Couture, P. Lau, F. Spagnolo, A.J. Alves Wainstein, D. Palmieri, C. Rojas García, G. de Velasco Oria de Rueda, I. Mehmi, D. Patel, A. Shaikh, N.R. Chowdhury, S. Bathena, S. Suryawanshi, P. Rutkowski
Format:	Article
Language:	English
Published:	Elsevier 2024-01-01
Series:	EJC Skin Cancer
Online Access:	http://www.sciencedirect.com/science/article/pii/S2772611824001319

Internet